Operating expenses are expected to be between 29 $1,000,000 $31,000,000 as we continue to make investments in people and technology. All this amount, depreciation and amortization are expected to be between $6,000,000 $6,500,000 while stock based compensation is expected to be between 2 point $7,000,000 $3,000,000 Given our large unrestricted and restricted cash balances and the current interest rate environment, we expect to generate interest income of $2,600,000 to $2,900,000 Taking all of the factors above into consideration, we expect net income to be in the range of 2,000,000 dollars to $3,000,000 or $0.04 to $0.06 per diluted share and adjusted EBITDA to be in the range of 8,000,000 dollars to $9,000,000 or $0.15 to $0.17 per diluted share. For the Q1 of 2024, we expect total revenue to be in the range of $12,000,000 to $13,000,000 reflecting the seasonal impact of tax refunds on our plasma business, offset with a strong start to the year with our patient affordability business. Gross profit margins are projected to be between 52% 3%, driven largely by an increased revenue contribution from our pharma patient affordability business. Operating expenses are expected to be between $7,000,000 to $7,500,000 of which depreciation and amortization will be approximately $1,300,000 This reflects investments largely required to support our pharma patient affordability growth.